Earnings call briefThird-quarter 2026
Sanofi says it now expects 2026 sales growth in the low teens percentage
Sanofi also said it now expects business EPS to grow at a mid-teen percentage, and CFO François Roger said that usually means 15% to 17%.
GetSignal Sanofi SNY
Sanofi said on its third-quarter call it is upgrading its 2026 guidance on strong business momentum to date. CFO François Roger said low teens percentage sales growth usually means 13% to 15%.
Sanofi also said it expects pricing to return to its historical pattern in 2027, a slightly negative contribution to global sales growth.
Quotes from the call
“We are upgrading our 2026 guidance to reflect the strong business momentum to date. We now expect sales to grow at a low teens percentage, which usually means a range of 13%-15%, and we expect business EPS to grow at a mid-teen percentage, which usually means between 15% and 17%.”
Key facts from the call
- Expected 2026 sales growth
- Low teens percentage, usually 13% to 15%
- Expected 2026 business EPS growth
- Mid-teen percentage, usually 15% to 17%
- Expected 2027 pricing contribution to global sales growth
- Slightly negative
- Expected 2027 sales reduction from Cheplapharm and Medley transactions
- Around EUR 1.3 billion
Source: Sanofi's third-quarter 2026 earnings call, October 30, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
